Study of Exosome Therapy Derived from Mesenchymal Stem Cells for Knee Osteoarthritis in Adults Aged 45 to 75

What this Trial Is About

Researchers are investigating the potential of exosomes derived from mesenchymal stem cells MSCs as a treatment for osteoarthritis OA, a joint disorder marked by cartilage damage and inflammation. OA involves increased activity of enzymes like MMP and ADAMTS that degrade the joint matrix. MSCs have been studied for OA due to their ability to release beneficial factors, including exosomes that carry bioactive molecules and anti-inflammatory agents, which may help regulate joint cell behavior and slow OA progression. The study evaluates the effects of allogenic MSC-derived exosomes given through two intra-articular injections into the knees on day 1 and day 90. Participants have moderate to severe OA in both knees Kellgren-Lawrence grade 2 or 3 with mild to moderate pain and swelling. This approach aims to assess the therapeutic potential of these exosome injections over time. Participants will be monitored over 6 months, with evaluations at 1, 3, and 6 months after the first injection. The main outcome measure is the Western Ontario and McMaster University Osteoarthritis Index WOMAC, which assesses pain, stiffness, and physical function. Researchers will observe changes following the initial and second injections, tracking the treatments impact on symptoms and joint health.

Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients